BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer
- website2646
- Jan 23, 2025
- 1 min read
top of page
Search
Recent Posts
See Allhttps://ir.bhtherapeutics.com/news-releases/news-release-details/blossomhill-therapeutics-announces-pricing-upsized-150-million
https://alamarbio.com/alamar-biosciences-announces-pricing-of-upsized-initial-public-offering/
xMEMS Introduces 1mm-Thin Active Micro Cooling “Fan on a Chip”
bottom of page
Comments